Sustained release T3 - also called slow release T3, SR-T3, or SRT3 - is the compounded, slow-release form of liothyronine (T3) used by researchers and patients who need T3 supplementation without the sharp serum peak that immediate-release T3 (Cytomel) produces. It is one of the most clinically relevant formulations in the entire thyroid research landscape, and one of the most poorly served by the commercial pharmaceutical pipeline.
This guide covers everything a researcher (or research-curious patient) needs to know about SR-T3 in 2026: how it differs from Cytomel and NDT pharmacokinetically, the dosing protocols most commonly used, the compounding-pharmacy landscape, why excipient quality matters more than most people realize, and what makes a clean SR-T3 formulation worth the premium over generic compounded versions.
Research Grade · Discreet Worldwide Shipping
SRT3-15 Slow Release T3
Research framing. This article reviews sustained-release T3 pharmacology, the published combination-therapy literature, and the dosing protocols most often discussed in clinical and research settings. It is not medical advice. T3 products on this site are sold as research reference standards and are not approved for human consumption. See our research-use-only disclaimer.
What Is Sustained Release T3?
Sustained release T3 (SR-T3) is liothyronine sodium - the synthetic version of triiodothyronine, the active form of thyroid hormone - formulated in a matrix that extends drug release over several hours instead of releasing all of it within ~30 minutes (as immediate-release Cytomel does).
The release is typically engineered with hydroxypropyl methylcellulose (HPMC), a pharmaceutical-grade cellulose derivative that swells in contact with stomach fluid and meters the dissolution of the embedded liothyronine. A typical SR-T3 capsule releases its dose over a 4-8 hour window, depending on the specific HPMC viscosity grade used in the compound.
The result is a serum T3 concentration curve that looks fundamentally different from Cytomel's:
| Formulation | Tmax (peak serum) | Peak height vs baseline | Effective duration |
|---|---|---|---|
| Cytomel (immediate-release T3) | ~2 hours | Sharp 3-5x spike | 12-24 hours, but the spike dominates |
| Sustained-release T3 (SR-T3) | ~4-6 hours | Gentle 1.5-2x rise | 8-12 hours, much flatter curve |
| NDT (natural desiccated thyroid) | ~3-4 hours (T3 portion) | Moderate spike on T3, sustained T4 backdrop | T3 effect 12-24 h, T4 effect days |
| Endogenous T3 | Pulsatile throughout the day | Smooth circadian rhythm | 24 h |
The SR-T3 curve is the closest commercially available approximation of how endogenous T3 actually pulses through the bloodstream. That single fact drives most of its clinical and research advantages.
Why Sustained Release T3 Matters: The Pharmacokinetic Case
The case for SR-T3 over Cytomel rests on four well-established pharmacokinetic facts:
- T3's serum half-life is ~24 hours, but its receptor occupancy half-life is much shorter. Cytomel produces a brief tissue-saturation event followed by a steep decline. The thyroid axis sees this as an oscillating signal rather than a steady one.
- Cardiovascular T3 receptors are more sensitive to peak concentration than to area-under-the-curve. Cytomel's sharp peak is the primary driver of palpitations, tachycardia, and the "wired" feeling that limits dosing in sensitive individuals.
- TSH suppression scales with serum T3 exposure, not just total dose. Slow-release T3 produces less TSH suppression per milligram than immediate-release T3 because the peak is lower, allowing more nuanced titration.
- Endogenous T3 release is pulsatile and circadian. Mimicking this pattern with sustained-release pharmacology is closer to physiology than dropping a bolus.
SR-T3 vs Cytomel: The Practical Differences
For researchers comparing the two formulations head-to-head, the differences that matter clinically:
| SR-T3 | Cytomel (immediate-release) | |
|---|---|---|
| Tmax | 4-6 hours | 2 hours |
| Side effect: palpitations | Substantially reduced | Common at moderate doses |
| Side effect: anxiety / "wired" feeling | Substantially reduced | Common at higher doses |
| TSH suppression per mg | Lower | Higher |
| Required doses per day | 1-2 | 2-4 (for steady levels) |
| Tolerable daily ceiling | Higher (smoother curve) | Lower (peak-limited) |
| Cost | Higher (compounded) | Lower (mass-manufactured) |
| Availability | Compounding pharmacies and research catalogs | Standard pharmacies |
| Stability | More variable; depends on compounding quality | Excellent (manufactured to USP) |
The practical summary: SR-T3 is the formulation of choice for anyone who wants to use T3 at meaningful doses without the side-effect ceiling Cytomel imposes. Cytomel is the right tool when low-dose, short-acting T3 is wanted (e.g., as an augmentation of T4 only at a single morning dose).
SR-T3 Dosing Protocols Most Commonly Used in Research and Clinical Practice
1. Wilson's WT3 cyclic protocol (highest-dose SR-T3 use)
Developed by Dr. Denis Wilson for Wilson's Temperature Syndrome - a clinical pattern of reverse-T3 dominance with low body temperature. This is the protocol most often discussed in the bioenergetic and chronic-illness research communities.
| Parameter | Standard SR-T3 protocol |
|---|---|
| Starting dose | 7.5 mcg every 12 hours |
| Titration | +7.5 mcg per dose every 1-3 days |
| Typical peak dose | 75-100 mcg every 12 hours |
| Target | Sustained oral body temperature ≥98.6°F (37.0°C) for 3 consecutive weeks |
| Weaning | Reduce by 7.5 mcg per dose every 1-3 days |
The aim is to overwhelm the deiodinase imbalance driving reverse-T3 dominance, then taper out, allowing endogenous T4-to-T3 conversion to resume.
2. Combination T4 + SR-T3 (most common clinical use)
For most hypothyroid research subjects, the SR-T3 is added on top of existing T4 (levothyroxine) rather than replacing it entirely. The most commonly cited ratio - based on ETA (European Thyroid Association) guidelines for combination therapy - is:
| Parameter | Combination protocol |
|---|---|
| T4 (levothyroxine) | Maintain existing dose; reduce by ~25 mcg if adding meaningful SR-T3 |
| SR-T3 | 5-15 mcg twice daily, titrated to symptom resolution and labs |
| T4:T3 ratio target | 13:1 to 16:1 by weight |
| Total SR-T3 per day | 10-30 mcg in most research subjects |
3. Pure SR-T3 monotherapy (rarely used clinically, more often in research)
| Parameter | Monotherapy protocol |
|---|---|
| Starting dose | 7.5-15 mcg twice daily |
| Titration | +7.5 mcg per dose weekly |
| Typical maintenance | 30-60 mcg/day in 2 divided doses |
| Endpoint | Symptom resolution; free T3 in upper third of reference range; suppressed TSH expected |
T3-only therapy is contentious in endocrinology but has been formally studied (Celi et al., J Clin Endocrinol Metab 2011) with results suggesting comparable thyroid hormone signaling to combination therapy in selected patients.
Common SR-T3 strengths and how they map to dosing
Research-grade SR-T3 is most commonly produced in these strengths, which align with the WT3 titration ladder:
| Strength | Use case |
|---|---|
| SRT3 7.5 mcg | Starting dose for Wilson's protocol; sensitive patients |
| SRT3 15 mcg | Standard combination-therapy dose; second titration step |
| SRT3 22.5 mcg | Titration step; intermediate maintenance |
| SRT3 45 mcg | Higher-dose Wilson's protocol; T3 monotherapy |
| SRT3 90 mcg | Peak Wilson's protocol; consolidation strength for stable patients |
Our SRT3 catalog carries all five strengths plus the Wilson's SRT3 Combo Kit for the full titration ladder.
Excipient Quality: Why It Matters More Than You'd Think
Compounded SR-T3 is not a homogeneous product. The same nominal "15 mcg sustained-release T3 capsule" can come with wildly different excipient profiles depending on the compounding pharmacy. Common excipient additions found in standard compounded SR-T3:
- Microcrystalline cellulose (MCC) - inert filler, safe
- HPMC (hydroxypropyl methylcellulose) - the slow-release matrix; required
- Magnesium stearate - lubricant; usually well tolerated
- Silica/silicon dioxide - flow agent; generally inert
- Dyes (FD&C Blue #1, Yellow #5/#6) - cosmetic only; common MCAS triggers
- Polyethylene glycol (PEG) variants - some patients react
- Lactose monohydrate - filler in some formulations; problematic for the lactose-intolerant
- Soy lecithin - in some formulations; allergen
- Talc - in older formulations; questioned
For research subjects with mast cell activation syndrome (MCAS), autoimmune chronic illness, or multi-allergen sensitivities - exactly the population most likely to need SR-T3 in the first place - excipient profile can determine whether the formulation is usable.
The cleanest SR-T3 you can specify is one that uses HPMC + MCC only. No dyes, no surfactants, no lactose, no gums, no PEG. Our SRT3 line is formulated exactly this way - two excipients total, no allergen-class additions. The 4-8 hour release window is provided by the HPMC matrix alone.
Compounding-Pharmacy Sourcing: What to Look For
Outside of research-catalog supply, SR-T3 must be obtained from a compounding pharmacy. The factors that matter most:
- PCAB or 503A accreditation. Pharmacy Compounding Accreditation Board (PCAB) accreditation is a quality marker beyond baseline state-board licensing.
- USP <797> compliance. Sterile and non-sterile compounding standards from the United States Pharmacopeia.
- Liothyronine API source documentation. A reputable compounding pharmacy will tell you where their liothyronine raw material comes from and provide a Certificate of Analysis (CoA) on request.
- Excipient disclosure. Should be available before you fill a prescription. If they won't tell you, walk away.
- Batch-to-batch consistency. Variation in compounded T3 strength is a known issue; pharmacies with strong QA programs are more consistent.
- HPMC viscosity grade. This determines actual release rate. Premium pharmacies use specific HPMC grades (e.g., HPMC K100M for ~8-hour release; HPMC K15M for ~4-hour); cheaper compounds use whatever bulk HPMC is on hand.
For research-only use (the framing for this site), HPLC-verified SR-T3 reference standards are available through the chronic-illness.st catalog with full CoA on request.
SR-T3 and Reverse T3: The Specific Use Case
Reverse T3 (rT3) is produced when T4 is deiodinated by the type 3 deiodinase (DIO3) instead of the type 1 or 2 deiodinase (DIO1/DIO2). Under stress, inflammation, fasting, or critical illness, the body shifts toward more rT3 and less active T3 production, a pattern examined in depth in our deiodinase dysfunction guide. rT3 occupies the T3 receptor without activating it - functionally suppressing thyroid signaling.
SR-T3 is the preferred formulation for clearing rT3 dominance because:
- T3 dosing itself suppresses TSH, which reduces T4 secretion, which reduces the substrate for rT3 production
- T3 directly downregulates DIO3 activity, shifting the deiodinase balance back toward T3 production
- Sustained-release T3 maintains the receptor saturation long enough for these adaptations to occur
Importantly, the same DIO1 impairment that creates the need for T3 supplementation also underlies the T3-to-T2 deiodinase dysfunction that can leave mitochondrial function undersupported even after rT3 is cleared.
The reverse-T3 framework focuses on the T4→T3 step. There's a second conversion - T3→T2 - that depends on the same deiodinase enzymes and can be impaired by the same dysfunction. For research subjects who plateau on SR-T3 alone, the T3→T2 bottleneck is increasingly discussed as the missing piece. See The T3→T2 Conversion Problem for the deep dive, and our new Wilson's T3+T2 Combo for the research-grade reference standard that pairs T3 and T2 at a 1:1 ratio.
The Wilson's protocol is essentially designed around this rT3-clearing mechanism. For a deep dive on reverse T3 pathophysiology and the FT3:rT3 ratio interpretation, see our reverse T3 complete guide.
Tools and Calculators
Two interactive tools that pair well with this guide:
- T3 dosing & conversion calculator - convert between T4 levothyroxine, immediate-release T3 (Cytomel), SR-T3, and NDT equivalents
- FT3:rT3 ratio calculator - convert lab values and interpret your ratio
Modern bioenergetic context. The SR-T3 formulation aligns closely with the Ray Peat framework's preference for direct T3 dosing over T4-only protocols, and is the cleanest research-grade reference standard for the thyroid component of the Peat-aligned protocol. See The Ray Peat Protocol: Complete 2026 Research Guide for the broader bioenergetic context that includes SR-T3 as the thyroid keystone.
Dosing, titration, and troubleshooting reference. This guide covers the methodology and pharmacokinetic case for SR-T3. For the practical companion that covers starting dose, titration schedule, timing, food/absorption, missed-dose handling, and the troubleshooting framework for T3 anxiety, palpitations, morning headache, insomnia, and non-response patterns, see the Slow Release T3 Dosing and Troubleshooting: The Complete 2026 Research Guide.
Frequently Asked Questions
What is sustained release T3?
Sustained release T3 (SR-T3, also called slow release T3 or SRT3) is liothyronine sodium formulated in a slow-release matrix - typically using hydroxypropyl methylcellulose (HPMC) - that extends T3 release over 4-8 hours instead of the ~2-hour peak of immediate-release Cytomel. The result is a flatter, more physiological serum T3 curve with fewer cardiovascular and adrenergic side effects.
How is SR-T3 different from Cytomel?
Cytomel (immediate-release liothyronine) reaches peak serum T3 in about 2 hours and produces a sharp 3-5x spike over baseline. SR-T3 reaches peak in 4-6 hours and produces a gentler 1.5-2x rise. The result: SR-T3 has substantially fewer palpitations and "wired" side effects, allows higher cumulative daily doses, and produces less TSH suppression per milligram than Cytomel.
What is the typical SR-T3 dose?
For combination therapy (T4 + T3): 5-15 mcg of SR-T3 twice daily, with total daily doses of 10-30 mcg. For Wilson's WT3 protocol (cyclic T3 for reverse-T3 dominance): start at 7.5 mcg every 12 hours, titrate up by 7.5 mcg per dose every 1-3 days until body temperature sustains at 98.6°F for 3 consecutive weeks. For T3 monotherapy (rare): typically 30-60 mcg/day in 2 divided doses.
What are the most common SR-T3 strengths?
The standard compounded SR-T3 strengths are 7.5 mcg, 15 mcg, 22.5 mcg, 45 mcg, and 90 mcg. These map directly to the Wilson's WT3 titration steps (each step is +7.5 mcg per dose). 7.5 mcg is the starting dose; 15 mcg is the most common combination-therapy maintenance dose; 22.5-45 mcg is used in higher Wilson's titration; 90 mcg is the peak consolidation strength.
Where can I get sustained release T3?
SR-T3 is not available from major commercial pharmacy chains - it must come from a compounding pharmacy or, for research purposes, from a research-grade reference standard supplier. When sourcing from a compounding pharmacy, look for PCAB accreditation, USP <797> compliance, willingness to disclose the API source and excipient list, and a clear statement of the HPMC viscosity grade (which determines actual release rate). For HPLC-verified research-only SR-T3 in the standard 5-strength range, see our SRT3 catalog.
Is SR-T3 safer than Cytomel?
For most patients, yes - in the practical sense that SR-T3 produces fewer dose-limiting side effects (palpitations, anxiety, sleep disruption) and allows more nuanced titration. Both formulations contain the same active molecule (liothyronine sodium), so they have the same long-term cardiovascular and bone safety profile per unit of active T3 exposure. The difference is in the peak-vs-area-under-the-curve pharmacokinetics, which determines acute tolerability.
Why do excipients matter in SR-T3?
The population most likely to need SR-T3 - patients with chronic illness, MCAS, autoimmune thyroid disease, multi-allergen sensitivities - is also the population most likely to react to common excipients (dyes, lactose, PEG, surfactants). Standard compounded SR-T3 often contains FD&C dyes, lactose, magnesium stearate, and/or PEG. A clean SR-T3 formulation should use HPMC + MCC only - the slow-release matrix and an inert filler - with no allergen-class additions.
What is the SR-T3 release window?
A typical compounded SR-T3 capsule releases its dose over a 4-8 hour window, depending on the HPMC viscosity grade used. Lower-viscosity HPMC (e.g., K15M) gives a ~4-hour release; higher-viscosity HPMC (e.g., K100M) gives a ~8-hour release. Twice-daily dosing (every 12 hours) provides effectively continuous T3 coverage across the waking hours.
Can SR-T3 be used with NDT (natural desiccated thyroid)?
Yes - some patients combine NDT for its T4 backbone with SR-T3 for additional T3 coverage when the T3 in NDT is not sufficient. The combination is uncommon but documented in research-community discussions. The challenge is dose tracking: NDT contains both T4 and T3, so adding SR-T3 requires reducing either NDT or supplementary T4 to avoid overdose. See our NDT vs SR-T3 vs Cytomel comparison for protocols.
How long does it take SR-T3 to work?
Acute effects (temperature rise, energy lift) often appear within 3-5 days of starting an effective dose. Lab changes (free T3 rise, free T4 fall if T4 is being reduced, TSH suppression) appear within 4-6 weeks - the standard thyroid pharmacology re-equilibration window. Symptom resolution for chronic conditions (Wilson's syndrome, hair loss, weight changes) typically takes 8-12 weeks at a stable maintenance dose.
Is sustained release T3 FDA-approved?
No FDA-approved sustained-release liothyronine product exists in 2026. SR-T3 is available exclusively through compounding pharmacies (under section 503A of the FD&C Act) or as research-grade reference standards. The active molecule, liothyronine sodium, is FDA-approved in immediate-release form (Cytomel and generics).
Closing Note
Sustained release T3 sits at an unusual intersection: it is one of the most clinically useful thyroid formulations for the patient populations most likely to need it, and one of the worst-served by the commercial pharmaceutical pipeline. The combination of pulsatile-T3 physiology, peak-driven Cytomel side effects, and the typical chronic-illness patient's excipient sensitivity makes a clean compounded SR-T3 - HPMC + MCC only, no dyes, no allergen fillers - the formulation of choice.
For HPLC-verified research-grade SR-T3 reference standards in the standard 5-strength range (7.5, 15, 22.5, 45, 90 mcg), see our SRT3 catalog. All compounds discussed in this article are sold strictly for laboratory study and are not approved for human consumption.